Cancer Institute, Mark Foundation Launch Collaboration to Evaluate Liquid Biopsy for More Accurate, Rapid Assessment of Response to Immunotherapy
July 31, 2020
July 31, 2020
NEW YORK, July 31 -- Cancer Research Institute issued the following news:
The Cancer Research Institute (CRI) and The Mark Foundation for Cancer Research have launched an innovative clinical trial that aims to demonstrate the utility of a novel, ultra-sensitive biomarker-directed blood test, or liquid biopsy, in assessing cancer patient responses to immunotherapy. If this and future studies show that this approach can more accurately characterize these responses to therapy, oncologi . . .
The Cancer Research Institute (CRI) and The Mark Foundation for Cancer Research have launched an innovative clinical trial that aims to demonstrate the utility of a novel, ultra-sensitive biomarker-directed blood test, or liquid biopsy, in assessing cancer patient responses to immunotherapy. If this and future studies show that this approach can more accurately characterize these responses to therapy, oncologi . . .